 |
|
Multiple Primary Melanomas in a CDKN2A Mutation Carrier Exposed to Ionizing Radiation
Mark J. Eliason, MD;
Chris B. Hansen, MD;
Marybeth Hart, MS;
Patricia Porter-Gill, BS;
Wei Chen, BM, MD;
Richard A. Sturm, PhD;
Glen Bowen, MD;
Scott R. Florell, MD;
Ronald M. Harris, MD, MBA;
Lisa A. Cannon-Albright, PhD;
Leonard Swinyer, MD;
Sancy A. Leachman, MD, PhD
Arch Dermatol. 2007;143(11):1409-1412.
ABSTRACT
| |
Background Recent research has shown a possible causal relationship between ionizing radiation exposure and melanoma. Individuals with mutations in CDKN2A (cyclin-dependent kinase inhibitor 2A), the major melanoma predisposition gene, have an increased susceptibility to melanoma-promoting exposures, such as UV light. We describe a patient from a familial melanoma pedigree with 7 primary melanomas on the right side of her body, the first occurring 5 years after exposure to atmospheric nuclear bomb testing in the 1950s.
Observations Physical examination revealed phototype I skin, red hair, and 26 nevi (14 on the right and 12 on the left side of her body). One nevus was larger than 5 mm, and 2 were clinically atypical. Sequence analysis demonstrated a known deleterious mutation in CDKN2A (G–34T) and homozygosity for a red hair color variant in MC1R (melanocortin 1 receptor) (R151C). Fluorescence in situ hybridization analysis of blood, fibroblasts, and melanocytes from both upper extremities ruled out mosaicism.
Conclusions Individuals such as this patient, who has CDKN2A and MC1R mutations, are likely to be more susceptible to environmental insults. A careful review of environmental exposures in these vulnerable cases may reveal cancer-promoting agents, such as ionizing radiation, that go unnoticed in less susceptible populations.
INTRODUCTION
Risk factors for melanoma include environmental insults (eg, blistering sunburns) and genetic factors underlying hair and eye color, skin type, many or atypical moles, and family history. Being a member of a melanoma-prone family is the most significant risk factor, increasing one's likelihood of developing a melanoma to 35 to 70 times that of the general population.1 The gene for cyclin-dependent kinase inhibitor 2A (CDKN2A or p16) is the major melanoma predisposition gene identified at present. p16 is a key regulator of G1/S cell cycle entry by controlling phosphorylation of retinoblastoma via inhibition of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6).2 Variants in the gene for the melanocortin 1 receptor (MC1R) alter the production of pigment, shifting the equilibrium from eumelanin to pheomelanin. MC1R is a low-penetrance melanoma susceptibility gene; heterozygotes for the R151C allele have a 2-fold increased risk, and homozygotes such as the patient described herein carry an approximate 4-fold risk to develop melanoma compared with the general population.3 Carriage of MC1R variants by those with the CDKN2A mutation confers an additional risk for melanoma development.4-7
The relationship between environmental and genetic factors is illustrated by international investigations of CDKN2A mutation carriers. The GenoMel, an international Melanoma Genetics Consortium (http://www.genomel.org/), reported that the lifetime prevalence of melanoma among individuals with CDKN2A mutations varied considerably by geographic locale.8 The lifetime incidence of melanoma was 58% in Europe, 76% in the United States, and 91% in Australia among CDKN2A carriers of similar ethnic backgrounds. Bishop et al8 suggested that this difference was best explained by the difference in UV exposure and UV sensitivity among the different populations. The CDKN2A mutation carrier population clearly represents the group most likely to develop melanoma, and through careful history and observation, researchers may be able to deduce other melanoma-promoting events that may not be obvious in the general population.
Ionizing radiation is a known mutagen and carcinogen. Long- and short-term exposures have been associated with leukemia and thyroid, breast, and lung cancers.9-10 Studies that tracked the rates of cancer in the atomic bomb survivors of Nagasaki and Hiroshima reported an increased rate of basal cell and squamous cell carcinomas, but not melanoma, among this exposed Japanese population. In 2005, Fink and Bates11 published a meta-analysis of melanoma in 7 cohorts of individuals with short- or long-term exposure to ionizing radiation. Most of these groups included large white populations, the race most susceptible to melanoma development, and not represented by the work on Nagasaki and Hiroshima survivors. The authors reported a statistically significantly increased relative risk of melanoma in 5 of their 7 cohorts, including a cohort of 3702 subjects involved in the 1957 above-ground nuclear testing.11
A large, retrospective analysis of individuals treated with ionizing radiation for hereditary retinoblastoma demonstrated a significantly elevated rate of melanomas in the treatment field.12 This would suggest that in genetically predisposed individuals, exposure to ionizing radiation can promote melanoma through the retinoblastoma pathway. The CDKN2A protein product, p16, regulates cell growth through the retinoblastoma pathway,13 but the effects of ionizing radiation on CDKN2A mutation carriers have yet to be studied. In a 2005 study of multiple primary melanomas (MPM) and CDKN2A mutations, Puig et al14 noted that one of their patients with MPM had a CDKN2A mutation and a history of long-term exposure to ionizing radiation. We herein describe a CDKN2A mutation carrier with 7 primary melanomas on the same side of her body and a unique history of exposure to ionizing radiation.
OBSERVATIONS
The patient is a white woman who underwent investigation for a history of MPM. Medical records and blood and tissue samples were collected for investigation.
Her medical history was remarkable for the development of a melanoma on her right ear at 28 years of age, treated by excision and a radical neck lymph node dissection (Figure 1). She subsequently developed 6 additional primary melanomas. Of the 7 total melanomas, 6 were found on the right side of her body and 1 was in the midline (Figure 2). A squamous cell carcinoma of her right upper lip was diagnosed in 1997. Other pertinent medical history includes a 46-year history of smoking, coronary artery disease with placement of 3 coronary artery stents, and polycythemia vera diagnosed at 63 years of age.
|
|
|
|
Figure 1. Right side of the patient's face at the time she underwent evaluation in our clinic. The right external ear had been removed approximately 40 years previously owing to melanoma and it healed well. The patient's phototype I skin, red hair, and external auditory canal are apparent.
|
|
|
|
|
|
|
Figure 2. The location of the melanoma sites in the patient. A, Locations are approximated by the dots. The red dot indicates a melanoma that occurred on the anterior surface of the participant. B, Location and diagnosis of melanoma. MM indicates melanoma; SSM, superficial spreading melanoma.
|
|
|
Her environmental exposure history was significant for 1 blistering sunburn before 20 years of age, with minimal sunbathing and no subsequent sunburns. She also reports 1 episode of intense exposure to ionizing radiation at 27 years of age that occurred in October 1958 in southern Utah and Nevada. The patient and her husband left the car in which they were traveling to observe an atmospheric nuclear detonation from an undetermined distance for 20 to 30 minutes. After leaving the blast site, the patient sat in the passenger side of the car, the side oriented toward the test site, riding with her arm outside the car. They noted a fine, sticky dust on the top of the car when they arrived home, consistent with nuclear fallout. The patient denies the development of nausea or other acute symptoms the day of the exposure.
Her family history includes a cousin with melanoma and melanoma in the children of another cousin. Multiple other cancer types were also described in her extended family.
PHYSICAL EXAMINATION
Pertinent findings included phototype I skin, green eyes, red hair, and mild freckling. On the right side of her body, the patient had 14 moles, 1 of which was atypical. No nevi were larger than 5 mm. She also had 12 well-healed biopsy and treatment scars. On the left side of her body, the patient had 12 moles, 1 larger than 5 mm and 1 with atypical features, and 5 well-healed biopsy scars.
LABORATORY TESTS
Results of routine laboratory tests, including complete blood cell count, liver function tests, and a lipid panel, were unremarkable other than an elevated hematocrit consistent with polycythemia vera. Sequencing of the CKDN2A gene and promoter region revealed a G–34T 5' UTR mutation known to be deleterious.15 No additional mutations were found within the coding region. The alternate reading frame gene was also sequenced and had no mutations. Sequencing of MC1R demonstrated that the patient was homozygous for the R151C mutation. Chromosomal studies were performed on melanocytes, peripheral blood, and fibroblasts. Tissue specimens were collected from both sides of the body. Metaphase cells analyzed from cultures of all these tissues revealed a normal female karyotype. Fluorescence in situ hybridization of all specimen types was performed, and no chromosomal abnormalities were found. Direct sequencing of MC1R was performed as previously described.4, 16-17
COMMENT
This is a unique case report of ionizing radiation exposure in an individual with a deleterious CDKN2A mutation and MPM. The patient had 7 primary melanomas during a course of about 30 years, starting late in her third decade of life. Her laboratory studies are significant for a deleterious CDKN2A mutation, homozygosity for an MC1R red hair color variant, and fluorescence in situ hybridization results that were negative for chromosomal aberrancy on either side of her body. Her physical examination revealed skin phototype I, red hair, numerous biopsy and excisional scars, and a random distribution of 26 nevi, 2 of which had atypical features. Most of her melanomas occurred in traditionally sun-protected areas. Her family history is consistent with hereditary melanoma.1
Many groups have investigated the correlation between MPM and CDKN2A mutations (Table).14, 18-24 Collectively, these groups have described 467 individuals with MPM, 70 of them (15.0%) with CDKN2A mutations. Not all groups specified the number of primary melanomas for each individual. Of the studies that did specify the number of primary melanomas,14, 18-19,23-24 5 of 311 cases (1.6%) had at least 7 primary melanomas. Even among individuals with CDKN2A mutations, it is rare to have 7 primary melanomas. Puig et al14 reported that among their 104 patients with MPM, only 3 had a second primary melanoma appear in proximity (defined as on the same extremity as the first melanoma).14 Our patient was initially seen with a grouping of 4 independent melanomas on the right side, 1 on the inner left thigh, and 3 melanomas close to one another on the right ear, right shoulder, and upper back area (Figure 2).
|
|
|
|
Table. Overview of Studies Published on CDKN2A Testing in Patients With MPMs
|
|
|
Her exposure history is significant for 1 blistering sunburn and her report of observing an above-ground nuclear test while traveling in Utah and Nevada. The time of the exposure she describes is chronologically consistent with Operation Hardtack II (September 12 to October 30, 1958), during which atmospheric nuclear testing took place in southern Nevada.25-26
Previous studies have linked exposure to ionizing radiation and nonmelanoma skin carcinomas, including leukemia and thyroid, breast, and lung cancers.9, 27-28 There are also several brief reports that have described an excess rate of polycythemia rubra vera in subjects exposed to the fallout of nuclear tests.29-30 Ionizing radiation has not been historically considered a promoting agent for melanoma, because many of the original studies that reviewed the cancer in atomic blast survivors in Japan did not identify melanoma as an outcome of interest.
The studies reviewed by Fink and Bates11 collectively totaled hundreds of thousands of individuals who were predominantly white, the population most susceptible to melanoma. In addition to the rates of melanoma, the authors reported which of these studies demonstrated an excess rate of leukemia as a means to distinguish which cohorts received a significant radiation exposure. Five of the 7 cohorts had elevated rates of leukemia and melanoma. The remaining 2 cohorts did not have excess melanoma or excess leukemia, suggesting that both did not receive sufficient irradiation to induce any malignancy. They conclude that melanoma has not always been considered a significant end point in epidemiological studies on ionizing radiation, which may have hampered identifying a potentially causal relationship between ionizing radiation and melanoma. They also recommend that future epidemiological studies of ionizing radiation consider inclusion of melanoma as an outcome of interest.11
It is not clearly understood why some patients with CDKN2A mutations never develop melanoma, whereas others with the same mutation and even in the same family seem exquisitely prone to the development of numerous primary lesions. We suggest that in our patient, the MPM may have been a result of the superimposition of environmental exposures (ionizing radiation) on her highly vulnerable genetic predisposition. The careful examination of phenotypic and environmental risk factors in the very vulnerable subpopulation of CDKN2A mutation carriers may be a strategy to identify and clinically verify risk factors less obvious in the general population.
AUTHOR INFORMATION
Correspondence: Sancy A. Leachman, MD, PhD, Department of Dermatology and Huntsman Cancer Institute Melanoma Program, University of Utah, 2000 Circle of Hope, Room 5242, Salt Lake City, UT 84112-5550 (sancy.leachman{at}hci.utah.edu).
Accepted for Publication: April 20, 2007.
Author Contributions: Dr Leachman had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Hansen, Bowen, Cannon-Albright, and Leachman. Acquisition of data: Eliason, Hart, Florell, Harris, Swinyer, and Leachman. Analysis and interpretation of data: Eliason, Porter-Gill, Chen, Sturm, and Leachman. Drafting of the manuscript: Eliason, Hansen, Hart, and Leachman. Critical revision of the manuscript for important intellectual content: Eliason, Hansen, Hart, Porter-Gill, Chen, Sturm, Bowen, Florell, Harris, Cannon-Albright, Swinyer, and Leachman. Administrative, technical or material support: Chen and Sturm. Study supervision: Leachman.
Financial Disclosure: None reported.
Funding Support: This study was supported by a grant from the Tom C. Matthews Jr Familial Melanoma Research Clinic, the Huntsman Cancer Foundation, grants R01CA102422 and M01RR00064 from the National Institutes of Health, and grant C06-RR11234 from the National Center for Research Resources.
Additional Contributions: April Alexander Larson provided intellectual contributions to the study. The Pedigree and Population Resource (with funding from the Huntsman Cancer Foundation) provided data and computing support related to the Utah Population Database.
Author Affiliations: Department of Dermatology, Health Sciences Center (Drs Eliason, Hansen, Sturm, Bowen, Florell, Harris, Swinyer, and Leachman and Ms Porter-Gill), Huntsman Cancer Institute Melanoma Program (Drs Eliason, Hansen, Bowen, Florell, Harris, and Leachman and Mss Hart and Porter-Gill), and Department of Medical Informatics (Dr Cannon-Albright), University of Utah, Salt Lake City; and Melanogenix Group, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia (Drs Chen and Sturm).
REFERENCES
| |
1. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetic Consortium. J Clin Oncol. 1999;17(10):3245-3251.
FREE FULL TEXT
2. Ruas M, Peters G. The p16INK4a/p16 tumor suppressor and its relatives. Biochim Biophys Acta. 1998;1378(2):F115-F177.
PUBMED
3. Palmer JS, Duffy DL, Box NF; et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet. 2000;66(1):176-186.
FULL TEXT
|
ISI
| PUBMED
4. Box NF, Duffy DL, Chen W; et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations [published online ahead of publication August 8, 2001]. Am J Hum Genet. 2001;69(4):765-773. .
FULL TEXT
|
ISI
| PUBMED
5. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA. Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2208-2212.
FREE FULL TEXT
6. Peris K, Fargnoli MC, Pacifico A; et al. CDKN2A and MC1R mutations in patients with sporadic multiple primary melanoma. J Invest Dermatol. 2004;122(5):1327-1330.
FULL TEXT
|
ISI
| PUBMED
7. Debniak T, Scott R, Masojc B; et al. MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk. Int J Cancer. 2006;119(11):2597-2602.
FULL TEXT
|
ISI
| PUBMED
8. Bishop DT, Demenais F, Goldstein AM; et al. Geographical variation in the penetrance of p16 mutations for melanoma. J Natl Cancer Inst. 2002;94(12):894-903.
FREE FULL TEXT
9. Ron E, Preston DL, Kishikawa M; et al. Skin tumor risk among atomic-bomb survivors in Japan. Cancer Causes Control. 1998;9(4):393-401.
FULL TEXT
|
ISI
| PUBMED
10. Preston DL, Simizu Y, Pierce D, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors, report 13: solid cancer and noncancer disease mortality: 1950-1997. Radiat Res. 2003;160(4):381-407.
FULL TEXT
|
ISI
| PUBMED
11. Fink CA, Bates MN. Melanoma and ionizing radiation: is there a causal relationship? Radiat Res. 2005;164(5):701-710.
FULL TEXT
|
ISI
| PUBMED
12. Kleinerman RA, Tucker MA, Tarone RE; et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23(10):2272-2279.
FREE FULL TEXT
13. Hayward NK. Genetics of melanoma predisposition. Oncogene. 2003;22(20):3053-3062.
FULL TEXT
|
ISI
| PUBMED
14. Puig S, Malvehy J, Badenas C; et al. Role of the CDKNA locus in patients with multiple primary melanomas. J Clin Oncol. 2005;23(13):3043-3051.
FREE FULL TEXT
15. Liu L, Dilworth D, Gao L; et al. Mutation of the p16 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet. 1999;21(1):128-132.
FULL TEXT
|
ISI
| PUBMED
16. Box NF, Wyeth JR, O’Gorman LE, Martin NG, Sturm RA. Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet. 1997;6(11):1891-1897.
FREE FULL TEXT
17. Sturm RA. Skin color and skin cancer: MC1R, the genetic link. Melanoma Res. 2002;12(5):405-416.
FULL TEXT
|
ISI
| PUBMED
18. Blackwood MA, Holmes R, Synnestvedt M; et al. Multiple primary melanoma revisited. Cancer. 2002;94(8):2248-2255.
FULL TEXT
|
ISI
| PUBMED
19. Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J. CDKN2A germline mutations in individuals with multiple cutaneous melanomas. Cancer Res. 2000;60(24):6864-6867.
FREE FULL TEXT
20. Monzon J, Liu L, Brill H; et al. Mutations in multiple primary melanomas. N Engl J Med. 1998;338(13):879-887.
FREE FULL TEXT
21. Auroy S, Avril MF, Chompret A; et al. Sporadic multiple primary melanoma case: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer. 2001;32(3):195-202.
FULL TEXT
|
ISI
| PUBMED
22. Mantelli M, Barile M, Ciotti P; et al. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet. 2002;107(3):214-221.
FULL TEXT
|
ISI
| PUBMED
23. MacKie RM, Andrew N, Lanyon WG, Connor JM. CDKN2A germline mutations in UK patients with familial melanoma and multiple primary melanomas. J Invest Dermatol. 1998;111(2):269-272.
FULL TEXT
|
ISI
| PUBMED
24. Eliason MJ, Larson AA, Florell SR; et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol. 2006;126(3):660-666.
FULL TEXT
|
ISI
| PUBMED
25. Sublette C. Operation Hardtack II: 1958—Nevada Test Site. Updated October 15, 1997. http://nuclearweaponarchive.org/Usa/Tests/Hardtack2.html. Accessed April 7, 2007.26. Operation HARDTACK II 1958 (DNA6026F). http://www.dtra.mil/newsservices/fact_sheets/print/index.cfm?factsheet=ntpr_hardtack2.cfm www.dtra.mil/rd/programs/nuclear_personnel/pdf/Operation%20HARDTACK%20II.pdf. Accessed August 27, 2007.27. Johnson CJ. Cancer incidence in an area of radioactive fallout downwind from the Nevada Test Site. JAMA. 1984;251(2):230-236.
FREE FULL TEXT
28. Boice JD Jr. Studies of atomic bomb survivors: understanding radiation effects. JAMA. 1990;264(5):622-623.
FREE FULL TEXT
29. Caldwell GG, Kelley DB, Heath CW Jr, Zack M. Polycythemia vera among participants of a nuclear weapons test. JAMA. 1984;252(5):662-664.
FREE FULL TEXT
30. Weinberg JB. Sequential development of polycythemia vera and chronic myelocytic leukemia in a patient following radiation exposure from nuclear weapons tests. Am J Med. 1989;87(1):121-123.
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
